Back to top

Analyst Blog

MannKind Corporation’s (MNKD - Analyst Report) loss of 15 cents per share in the first quarter of 2013 was narrower than the Zacks Consensus Estimate of a loss of 16 cents and the year-ago loss of 27 cents per share.

Quarter in Detail

MannKind did not generate any revenue in the first quarter of 2013 as in the year-ago quarter.

Research and development (R&D) expenses increased 9.3% to $26.4 million in the reported quarter. The increase in R&D expenses was primarily attributable to higher costs for clinical trial-related activities during the quarter.

MannKind is primarily focusing on the development of its lead pipeline candidate Afrezza. Afrezza, an inhaled insulin, is being developed for the treatment of type I (Affinity 1 study) or type II (Affinity 2 study) diabetes.

General and administrative expenses increased approximately 2.7% in the reported quarter to $10.0 million. The increase was primarily attributable to higher non-cash stock based compensation expenses.

MannKind’s cash burden during the first quarter of 2013 was $33.5 million as compared to $25.9 million in the fourth quarter of 2012.

Our View

We expect investor focus to remain on Afrezza going forward. MannKind expects to present results on Afrezza in mid-August this year. The company plans to resubmit the New Drug Application (NDA) for the candidate in late September or early October this year.

MannKind currently carries a Zacks Rank #2 (Buy). Other biopharma stocks, such as Jazz Pharmaceuticals (JAZZ - Analyst Report), Santarus Inc. and Cubist Pharmaceuticals Inc. (CBST - Analyst Report) are comparatively well placed. While Jazz Pharma and Santarus carry a Zacks Rank #1 (Strong Buy), Cubist Pharma carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%
NUSTAR GP H… NSH 41.14 +2.59%